Eaton Vance Management Novo Cure LTD Transaction History
Eaton Vance Management
- $67.5 Billion
- Q3 2022
A detailed history of Eaton Vance Management transactions in Novo Cure LTD stock. As of the latest transaction made, Eaton Vance Management holds 36,093 shares of NVCR stock, worth $765,532. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,093
Previous 34,639
4.2%
Holding current value
$765,532
Previous $2.41 Million
13.87%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding NVCR
# of Institutions
272Shares Held
74.3MCall Options Held
1.17MPut Options Held
318K-
Black Rock Inc. New York, NY12.1MShares$257 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$250 Million0.01% of portfolio
-
Capital International Investors Los Angeles, CA7.92MShares$168 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA4.31MShares$91.4 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.81MShares$59.5 Million0.03% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $2.23B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...